Established in 2013, Polpharma Biologics is the biotechnology unit of the rapidly growing Polpharma Group one of the largest pharmaceutical players in the CEE region. Currently, with over 140 people, four sites, and full expertise for biopharmaceutical development and production, Polpharma Biologics is running five projects dedicated to monoclonal antibodies, and is just stepping into the contract development and manufacturing business.
Bonesupport is planning €60m IPO
Latest NewsSwedish orthobiologics company Bonesupport Holding AB announced on Sunday it will go public at Nasdaq Stockholm.
Targovax raises €21m in private placement
Latest NewsNorwegian cancer med developer Targovax ASA has doubled its cash and cash equivalents as of 31 December 2016 by raising NOK200m (€21m) in a private placement of new shares.
Luminary in vaccine research
AppointmentsGrünenthal in US$300m deal with AstraZeneca
Latest NewsGerman Grünenthal Group has entered into an agreement to acquire the global rights to AstraZeneca’s migraine treatment Zolmitriptan.
Biocartis launches partnership in liquid biopsy
Latest NewsBelgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.
The Difference of One Simple Sort
Sponsored PublicationsOne researcher, one sorter, one cell, many discoveries. BD is dedicated to developing easy-to-use cell sorting technologies that simplify accurate and reliable flow cytometry.
Biomanufacturing: Why single-use?
OpinionPharmalink: Launching into Phase III
AppointmentsMerck KGaA and F-star in €1bn deal
Latest NewsGerman Merck KGaA has secured an option on UK’s F-Star Biotechnology Ltd’s preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage.
Metrion Biosciences: Developing the business
Appointments